Singlomics Announces First Patient Dosed in Phase I Clinical Trial of DXP-106 (IL-1RAP mAb) in China Written by PR Newswire Enable JavaScript and cookies to continueRead more http://www.prnasia.com/story/archive/4928431_CN28431_0